3 / 27
Page 57
Notes:
allied
academies
J Pharmacol Ther Res 2017 Volume 1 Issue 2
November 02-03, 2017 Chicago, USA
4
th
International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
In silico, in vitro
and
in vivo
studies for analyzing the propranolol action on cholinergic and carbonic
anhydrase systems
Emily L Castillo-García, Marvin A Soriano-Ursúa, Fabiola J Ciprés-Flores, Erik Andrade-Jorge
and
Eunice D Farfán-García
Instituto Politécnico Nacional, Mexico
P
ropranolol is a well-known antagonist of adrenergic
receptors. In fact, it is classified as a non-selective blocker
of beta-adrenergic receptors. However, several other
biological activities have been suggested or demonstrated
to that molecule. On the other hand, it is known this drug
can be active on Central Nervous System (CNS) after oral
administration due to its ability to entering trough the blood
brain barrier after this pathway. In this work, we tested
the activity of propranolol on the cholinergic and carbonic
anhydrase systems, which together with the adrenoceptor
systems are considered related to potential therapeutic
target to CNS-disorders, particularly, those related to
cognitive deficit. We approach this topic by
in silico
assays
on acetylcholinesterase and carbonic anhydrase showing
the ability of this compound to interact on the active sites
and potentially exert an effect on these sites. But also, we
used these enzymes
in vitro
for observing the capability of
this compound to inhibit their action. Finally, we corroborate
the improvement of performance in passive avoidance task
after its administration in male rats with cognitive deficit
induced by orchiectomy. By taking all together, our results
suggest the attractiveness to study propranolol as a multi-
target drug modulating the cognitive processes for treating
CNS disorders.
Speaker Biography
Emily L Castillo-García has completed her training as Biochemistry Engineer in Instituto
Tecnológico de Acapulco, Guerrero, Mexico. She is working in Medicinal Chemistry
Research and neuroscience projects the last three years. She is particularly interested
in the action of some molecules on neurodegenerative disease: steroid hormones,
adrenergic agents and enzyme inhibitors. Currently, she is enrolled in Master in Health
Sciences program in Escuela Superior de Medicina del Instituto Politécnico Nacional.
Her research-advances have been presented in several national and international
congresses.
e:
emily.castillo.ibq@gmail.com